tbuckley/cabot-search huggingface dataset:
More memory?
Authors: Irene Grote
Journal: Behavioral and Brain Sciences (2003)

Modern investigators of cognition ask about the conditions under which faculties occur rather than about their existence. This tendency, combined with the axiom of parsimony, emphasizes a paradigm shift in the fundamental principles of economic thought in science, mimicking evolutionary conceptualizations. The Ruchkin model of memory-related brain activity replaces less economic models. From interdisciplinary approaches, proceduralist models for other memory-related processes analogously support this model.
Obituary: Fred Mosteller
Journal: BMJ (2006)

serogroup A organisms.Travellers to this area and pilgrims on the annual Hajj to Mecca are advised to be immunised against serogroup A disease.Vaccines for group B disease suitable for routine use in young children have not so far been developed.The possibility of protection against meningococcal disease by blocking pharyngeal binding with Neisseria lactamica is intriguing, w9 but it only tackles one aspect of the predisposing conditions for meningococcal infection.Competing interests: Both authors have received research grants from the Meningitis Research Foundation.APJT acts as an expert witness
Phase III Trial of Fluorouracil, Interferon Alfa-2b, and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Metastatic or Unresectable Urothelial Cancer
Authors: Arlene O. Siefker-Radtke, Randall E. Millikan, Shi-Ming Tu, Dennis F. Moore, Terry L. Smith, Dallas Williams, Christopher J. Logothetis
Journal: Journal of Clinical Oncology (2002)

PURPOSE: Previously, we developed a novel biochemotherapy regimen combining interferon alfa-2b with fluorouracil and cisplatin (FAP). We now report the results of a prospective randomized trial comparing FAP with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC), the standard chemotherapy regimen for locally advanced and metastatic urothelial cancer. The purpose of this study was to compare the response rates and overall survival of patients with metastatic or unresectable urothelial cancer treated with these two chemotherapy regimens. PATIENTS AND METHODS: Between October 1992 and September 1999, 172 previously untreated patients were registered and randomly assigned to treatment with either FAP or M-VAC. Patients were followed until their death. RESULTS: The pretreatment clinical characteristics of the groups were similar except for sex (P &lt; .01). Sex did not affect prognosis or survival. The objective response rate for patients assigned to FAP was 42% (35 of 83 patients), with complete response observed in eight (10%) of 83 patients. Among the patients assigned to M-VAC, 51 (59%) of 86 had an objective response, with complete response observed in 21 (24%) of 86. The Kaplan-Meier estimate of median survival was 12.5 months for both groups. Both regimens were quite toxic, with more mucocutaneous toxicity in the FAP arm and more myelosuppression in the M-VAC arm. CONCLUSION: Although overall survival was not significantly different, patients assigned to M-VAC had a much better chance of responding to front-line therapy. Thus, FAP is very likely to be inferior to M-VAC and is certainly no less toxic. FAP cannot be recommended as part of the standard armamentarium for urothelial cancer.
Sane: Insane
Journal: JAMA (1973)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Patient compliance and drug failure in protease inhibitor monotherapy
Authors: G. F. Vanhove
Journal: JAMA (1996)

<h3>To the Editor.</h3> —We conducted a 2-dose study of saquinavir in which 40 human immunodeficiency virus type 1 (HIV-1)positive patients received either three or six 200-mg capsules of saquinavir (Roche Products, Welwyn, United Kingdom) 6 times daily (total dose, 3600 mg/d or 7200 mg/d).<sup>1</sup>Analysis of an early cohort of patients enrolled in the study demonstrated that the duration of the response as measured by HIV-1 plasma RNA copy number varied widely within the 2 groups. This variation was not accounted for by the development of resistant mutations alone. To investigate whether decreased patient compliance with this intensive regimen could explain the observed variation in viral responses, we monitored drug-taking behavior in the remaining patients on their enrollment into the high-dose group for the initial 24 weeks of therapy using medication container closures or caps that record the precise date and time of the opening and closing of the
Error in Table 3
Journal: JAMA Network Open (2020)

Alexander F. Bagley, MD, PhD; Mitchell S. Anscher, MD; Seungtaek Choi, MD; Steven J. Frank, MD; Karen E. Hoffman, MD; Deborah A. Kuban, MD; Sean E. McGuire, MD, PhD; Quynh-Nhu Nguyen, MD; Brian Chapin, MD; Ana Aparicio, MD; Todd A. Pezzi, MD, MBA; Grace L. Smith, MD, PhD, MPH; Benjamin D. Smith, MD; Kenneth Hess, PhD; Chad Tang, MD
Prevalence of carrier status in relatives of naxos disease patients Nikos Protonotarios, Adalena Tsatsopoulou, Aris Anastasakis, Antigone Miliou, Elias Sevdalis, Angelos Rigopoulos, Artemisia Theopistou, Godfrina McCoy, Christodoulos Stefanadis, Pavlos Toutouzas. Department of Cardiology, University of Athens, Athens, Greece, J. Protonotarios Medical Center, Naxos, Greece
Journal: Journal of the American College of Cardiology (2001)
Miscellanea edica
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 3184: Dynamics of Mitral Complex Geometry During Left Ventricular Pressure Overload: in Vivo Experimental Study by Real-time 3D Echocardiography
Authors: Ryotaro Yamada, Nozomi Watanabe, Teruyoshi Kume, Miwako Tsukiji, Kikuko Obase, Takahiro Kawamoto, Yoji Neishi, Akihiro Hayashida, Eiji Toyota, Hiroyuki Okura, Kiyoshi Yoshida
Journal: Circulation (2007)

Background: Functional mitral regurgitation (MR) occurs as a consequence of regional or global left ventricular (LV) dysfunction despite a structurally normal mitral valve (MV). Degree of MV coaptation should be an important parameter in the assessment of functional MR. Purpose: We sought to investigate the change of MV coaptation and to clarify relationship between MV coaptation and development of MR in LV pressure overload. Methods: Using a canine model, LV pressure overload was induced by staged aortic banding (60 to 120mmHg). Echocardiographic examinations were performed before and during the banding. Degree of MR was evaluated by tracing the color jet MR area (MR area). By using a novel software system (RealView TM ) for 3D quantification, mitral annulus (MA) area, tenting volume, tenting length and 3D tenting surface area were analyzed. MA and surface of MV was manually traced both at the onset of MV closure [O] and at the maximum MV closure [M]. Coaptation index was calculated by the difference in 3D tenting surface area at O and at M devided by that at O. Results: MA area was gradually increased during banding ( p &lt; 0.01). Tenting length and tenting volume tended to increase during banding but they did not reach statistical significance (tenting length; p = 0.17, tenting volume; p = 0.12). MR area increased with decrease in coaptation index (Figure ). The best cutoff value of the coaptation index to predict presence of MR was calculated as 0.24, giving a sensitivity of 82 % and specificity of 86 %. Conclusions: During aortic banding, MA dilated and coaptation of the MV decreased with apparent leaflet tenting. Coptation index might be able to predict the appearance of functional MR.
The Malarial Therapy of General Paralysis and Other Conditions
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CONJUNCTIVITIS MEIBOMIANÆ.
Authors: JAMES A. LYDSTON
Journal: JAMA (1894)

Notwithstanding the many varieties of conjunctivitis, the above title suggests itself as being particularly descriptive of a variety of lid inflammation which has recently fallen under my observation and care. The condition in the case that I have noted was so strikingly characteristic that no other cause could possibly be defined as the source of the inflammatory reaction, but a microbic or chemical irritation induced by the extrusion of the decomposed secretion from the meibomian glands, and hence the above name seems particularly suggestive and appropriate. To my knowledge, no one has described such a condition, and I am unable to find any reference to the subject in the ophthalmologic literature at my command. The appearance of the conjunctival tarsi was quite picturesque, there being irregular, island-shaped, roseate elevations distributed over its entire surface (with distinct and well defined interspaces of uninflamed conjunctival structure,) which were marked like the efflorescence
Pacinian collagenoma
Authors: None Pillay, None Essa, None Chetty
Journal: British Journal of Dermatology (1999)

An unusual histological variant of collagenoma is described. A 36‐year‐old woman presented with a lump in the left hypothenar eminence. Histological examination revealed a well‐delineated lesion composed of paucicellular collagen fibres arranged in concentric lamellations giving rise to an onion skin appearance. The overlying epidermis was thin and the lateral borders were demarcated by an epidermal collarette. Inflammation and xanthoma cells were absent and occasional capillaries were present. The lesion was positive for collagen stains, reticulin and CD34. This lesion represents an uncommon histological form of collagenoma or fibroma. It can be distinguished from histological look‐alikes on the basis of the characteristic morphology and immunophenotype.
Treatment with the endothelin receptor inhibitor bosentan alleviates the NAFLD-associated increased intrahepatic vascular resistance and reduces steatosis and liver damage in a rat model of early NAFLD
Authors: Denise van der Graaff, Wilhelmus Kwanten, Peter Michielsen, Joris De Man, Benedicte De Winter, Sven Francque
Journal: Journal of Hepatology (2020)
Error in Table.
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Revenant
Authors: Bhuvana Chandra
Journal: Annals of Internal Medicine (2015)

Ad Libitum17 March 2015RevenantBhuvana Chandra, MDBhuvana Chandra, MDFrom Porter Ranch, California.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M14-2248 Audio Reading - “Revenant” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Revenant," by B. Chandra. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail (in honor of A.M.)So! You have returned. Cagey you. No upfrontherald, just a sneaky cough. Why, of course.How long has it been? You should know. It's beenages since I shed anticipatory dread along withmy breasts. How better to best a perfidious foe?Let's see. Since you last went away, I've beena busy, busy girl. Taking life fast by the throatrequires a certain je ne sais quoi; shaking the hellout of it demands chutzpah. Guess what?Yours truly (in all modesty) excels in both.along with those nodes, replaced my lost copy... Author, Article, and Disclosure InformationAffiliations: From Porter Ranch, California.Current Author Email Address: [email protected]rr.com. PreviousarticleNextarticle Advertisement Audio Reading - “Revenant” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Revenant," by B. Chandra. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 17 March 2015Volume 162, Issue 6Page: 428KeywordsBone marrowCellsChildrenFallsFearHand strengthPharynxShockThorax ePublished: 17 March 2015 Issue Published: 17 March 2015 Copyright & PermissionsCopyright © 2015 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
EPIDEMIC TYPHOID FEVER AT WATERBURY, CONNECTICUT.
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
American Journal of Epidemiology, Baltimore
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
(7) Genetic control of sebum excretion and acne—a twin study
Authors: S.H. Walton, E.H. Wyatt, W.J. Cunliffe
Journal: British Journal of Dermatology (1987)

Twin studies have shown the almost 100% occurrence of acne in identical twins, but the authors did not compare the severity of acne nor sebum excretion rate. We have investigated 20 sets of identical and 20 sets of non-identical twins. The acne was graded by the Burke and Cunliffe technique1 and sebum excretion measured by the gravimetric technique.2 The non-identical twins had dissimilar levels of sebum excretion (P < 0·01) and acne (P < 0·01). However, although identical twins had virtually identical rates of sebum excretion, they displayed a significantly different degree of acne severity (P < 0·01). These results were contrary to our hypothesis that identical twins would probably have a similar degree of acne severity. We concluded that sebum excretion is under genetic control but the development of lesions is modified by environmental factors, the most likely factors being variation in the growth rate of Propionibacterium acnes and its production of biological mediators of inflammation.
Study of i.v. drug users and AIDS finds differing infection rate, risk behaviors
Authors: C. A. Raymond
Journal: JAMA (1988)

A CHICAGO study of intravenous (IV) drug users and acquired immunodeficiency syndrome (AIDS) paints a more complex picture of this population and indicates that one of the common sources of national seroprevalence monitoring may be missing sizable pockets of human immunodeficiency virus (HIV) infection, delaying timely intervention. The AIDS Outreach Intervention Project, based at the University of Illinois at Chicago, has a three-year, $3.2 millon grant from the National Institute on Drug Abuse (NIDA), Rockville, Md, to assess HIV seroprevalence among IV drug abusers and the most effective approaches to reduce viral transmission in this population. Wayne Weibel, PhD, principal investigator for the national project, presented data on the Chicago portion of the study at the annual meeting of the American Public Health Association in Boston. Denver, El Paso, Tex, and Baltimore are using the same protocol but are not ready to report results. In Chicago, persons skilled in working
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
Authors: Aurélien Marabelle, Holbrook Kohrt, Idit Sagiv-Barfi, Bahareh Ajami, Robert C. Axtell, Gang Zhou, Ranjani Rajapaksa, Michael R. Green, James Torchia, Joshua Brody, Richard Luong, Michael D. Rosenblum, Lawrence Steinman, Hyam I. Levitsky, Victor Tse, Ronald Levy
Journal: Journal of Clinical Investigation (2013)

Activation of TLR9 by direct injection of unmethylated CpG nucleotides into a tumor can induce a therapeutic immune response; however, Tregs eventually inhibit the antitumor immune response and thereby limit the power of cancer immunotherapies. In tumor-bearing mice, we found that Tregs within the tumor preferentially express the cell surface markers CTLA-4 and OX40. We show that intratumoral coinjection of anti–CTLA-4 and anti-OX40 together with CpG depleted tumor-infiltrating Tregs. This in situ immunomodulation, which was performed with low doses of antibodies in a single tumor, generated a systemic antitumor immune response that eradicated disseminated disease in mice. Further, this treatment modality was effective against established CNS lymphoma with leptomeningeal metastases, sites that are usually considered to be tumor cell sanctuaries in the context of conventional systemic therapy. These results demonstrate that antitumor immune effectors elicited by local immunomodulation can eradicate tumor cells at distant sites. We propose that, rather than using mAbs to target cancer cells systemically, mAbs could be used to target the tumor infiltrative immune cells locally, thereby eliciting a systemic immune response.